References
- ArapWPasqualiniRRuoslahtiECancer treatment by targeted drug delivery to tumor vasculatur in a mouse modelScience199827953493773809430587
- DavisMEChenZGShinDMNanoparticle therapeutics: an emerging treatment modality for cancerNat Rev Drug Discov20087977178218758474
- Ec-YTChewYPhippsCA review of monoclonal antibody therapies in lymphomaCrit Rev Oncol/Hematol2016977284
- LiuDAugusteDTCancer targeted therapeutics: from molecules to drug delivery vehiclesJ Control Release201521963264326342659
- XuXHoWZhangXBertrandNFarokhzadOCancer nanomedicine: from targeted delivery to combination therapyTrends Mol Med201521422323225656384
- ScottSDRituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphomaCancer Pract1998631951979652253
- MclaughlinPGrillo-LópezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
- VegaMIHuerta-YepezSMartinez-PaniaguaMRituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functionsClin Cancer Res200915216582659419861448
- SimonsKToomreDLipid rafts and signal transductionNat Rev Mol Cell Biol200011313911413487
- MaloneyDGSmithBRoseARituximab: mechanism of action and resistanceSemin Oncol200229129
- HofmeisterJKCooneyDCoggeshallKMClustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosisBlood Cells Mol Dis200026213314310753604
- PopoffIJSavageJABlakeJJohnsonPDeansJPThe association between CD20 and Src-family Tyrosine kinases requires an additional factorMol Immunol19983542072149736336
- JazirehiARVegaMIBonavidaBDevelopment of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapyCancer Res20076731270128117283164
- BubienJKZhouLJBellPDFrizzellRATedderTFTransfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytesJ Cell Biol19931215112111327684739
- TanLLinPChistiMMRehmanAZengXReal time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cellsAnal Chem201385188543855123926879
- DanielsITurzanskiJHaynesAPA requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Ritux-imabBr J Haematol2008142339440318544085
- JaffeESHarrisNLSteinHIsaacsonPGClassification of lymphoid neoplasms: the microscope as a tool for disease discoveryBlood2008112124384439919029456
- ChenWZhengRZhangSCancer incidence and mortality in China, 2013Cancer Lett20174011637128476483
- SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
- SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
- SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
- FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer20134961374140323485231
- CoiffierBRituximab therapy in malignant lymphomaOncogene200726253603361317530014
- LeeNYooDLingDChoMHHyeonTCheonJIron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive TherapyChem Rev201511519106371068926250431
- BabesLDenizotBTanguyGLe JeuneJJJalletPSynthesis of iron oxide Nanoparticles used as MRI contrast agents: a parametric studyJ Colloid Interface Sci1999212247448210092379
- JordanAScholzRWustPFählingHFelixRolandFelixRMagnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticlesJ Magn Magn Mater19992011–3413419
- ArbabASBashawLAMillerBRCharacterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imagingRadiology2003229383884614657318
- JanicBRadAMJordanEKOptimization and validation of FePro cell labeling methodPLoS One200946e587319517015
- XuCXuKGuHDopamine as a robust anchor to immobilize functional molecules on the iron oxide shell of magnetic nanoparticlesJ Am Chem Soc2004126329938993915303865
- HuhYMJunYWSongHTIn vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystalsJ Am Chem Soc200512735123871239116131220
- LeeJHHuhYMJunYWArtificially engineered magnetic nanoparticles for ultra-sensitive molecular imagingNat Med2007131959917187073
- ChiuGNEdwardsLAKapanenAIModulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructsMol Cancer Ther20076384485517339368
- LaurentSForgeDPortMMagnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applicationsChem Rev200810862064211018543879
- ChisolmJJJjcJSafety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrationsJ Toxicol Clin Toxicol200038436537510930052
- FauconnierNPonsJNRogerJBeeAThiolation of Maghemite Nanoparticles by Dimercaptosuccinic AcidJ Colloid Interface Sci199719424274339398425
- ValoisCRBrazJMNunesESThe effect of DMSA-functionalized magnetic nanoparticles on transendothelial migration of monocytes in the murine lung via a beta2 integrin-dependent pathwayBiomaterials201031236637419822361
- MaclaughlinCMParkerEPWalkerGCWangCEvaluation of SERS labeling of CD20 on CLL cells using optical microscopy and fluorescence flow cytometryNanomedicine201391556422542823
- ErnstJALiHKimHSNakamuraGRYansuraDGVandlenRLIsolation and characterization of the B-cell marker CD20Biochemistry20054446151501515816285718
- CraggMSWalsheCAIvanovAOGlennieMJThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun2005814017415564720
- XieJChenKHuangJPET/NIRF/MRI triple functional iron oxide nanoparticlesBiomaterials201031113016302220092887
- JohnsonPGlennieMThe mechanisms of action of rituximab in the elimination of tumor cellsSemin Oncol200330138
- Cirstoiu-HapcaABossy-NobsLBucheggerFGurnyRDelieFDifferential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticlesInt J Pharm2007331219019617196347
- RochAGossuinYMullerRNGillisPSuperparamagnetic colloid suspensions: Water magnetic relaxation and clusteringJ Magn Magn Mater20052931532539
- BerretJFSchonbeckNGazeauFControlled clustering of superparamagnetic nanoparticles using block copolymers: design of new contrast agents for magnetic resonance imagingJ Am Chem Soc200612851755176116448152
- VegaMIHuerta-YepezSMartinez-PaniaguaMRituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functionsClin Cancer Res200915216582659419861448
- GaoLFeiJZhaoJLiHCuiYLiJHypocrellin-loaded gold nanocages with high two-photon efficiency for photothermal/photodynamic cancer therapy in vitroACS Nano2012698030804022931130
- PintonPGiorgiCSivieroRZecchiniERizzutoRCalcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosisOncogene200827506407641818955969
- ShanDLedbetterJAPressOWApoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodiesBlood1998915164416529473230
- BubienJKZhouLJBellPDFrizzellRATedderTFTransfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytesJ Cell Biol19931215112111327684739
- LiHAyerLMPolyakMJThe CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanismJ Biol Chem200427919198931990114976189
- PolyakMJDeansJPAlanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structureBlood20029993256326211964291
- MartindaleJLHolbrookNJCellular response to oxidative stress: signaling for suicide and survivalJ Cell Physiol2002192111512115731
- MachoAHirschTMarzoIGlutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosisJ Immunol199715810461246199144473
- GreenDRReedJCMitochondria and apoptosisScience19982815381130913129721092
- GalluzziLZamzamiNde La Motte RougeTLemaireCBrennerCKroemerGMethods for the assessment of mitochondrial membrane permeabilization in apoptosisApoptosis200712580381317294081
- SusinSAZamzamiNKroemerGMitochondria as regulators of apoptosis: doubt no moreBiochim Biophys Acta199813661–21511659714783
- YouleRJStrasserAThe BCL-2 protein family: opposing activities that mediate cell deathNat Rev Mol Cell Biol200891475918097445
- XiangJChaoDTKorsmeyerSJBAX-induced cell death may not require interleukin 1β-converting enzyme-like proteasesProc Nat Acad Sci U S A199693251455914563
- ShimizuSNaritaMTsujimotoYBcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDACNature1999399673548348710365962
- AdamsJMCorySThe Bcl-2 protein family: arbiters of cell survivalScience19982815381132213269735050
- EmmanouilidesCJazirehiARBonavidaBRituximab-mediated sensitization of B-non-Hodgkin’s lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbineCancer Biother Radiopharm200217662163012537665
- CartronGWatierHGolayJSolal-CelignyPFrom the bench to the bedside: ways to improve rituximab efficacyBlood200410492635264215226177
- JazirehiARBonavidaBCellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic interventionOncogene200524132121214315789036
- LalatonneYRichardiJPileniMPVan der Waals versus dipolar forces controlling mesoscopic organizations of magnetic nanocrystalsNat Mater20043212112514730356
- DobsonJRemote control of cellular behaviour with magnetic nanoparticlesNat Nanotechnol20083313914318654485